GEn1E is a next generation biotechnology company turbocharging cures for rare and neglected diseases. GEn1E's unique solution is a hack to the biotech industry, getting medicines to the market 10X cheaper, 2X faster and 2X more likely to succeed than conventional therapies.Our lead program are Selective p38 alpha kinase inhibitors which provide a platform for the treatment of various aging and inflammatory diseases. Our first indication will be for a rare disease, Acute Lung injury (ALI)/Acute Respiratory Distress Syndrome (ARDS)- a disease with no FDA approved treatments, a mortality of 40% and a $20 Billion cost to society

Gen1E Lifesciences

Gen1E Lifesciences